Ankura Hospitals Secures Rs 165 Cr Funding from ADB to Expand Healthcare Services

Chithra Prakash
Chithra Prakash
· 2 min read

The investment aligns with the hospital chain’s vision of enhancing accessibility to high-quality pediatric, maternity and gynaecology services across India

Ankura Hospitals, a leading Hyderabad-based super-speciality healthcare provider, has secured Rs 165 crore in funding from the Asian Development Bank (ADB) to support its expansion and strengthen its market presence. The investment aligns with the hospital chain’s vision of enhancing accessibility to high-quality pediatric, maternity and gynaecology services across India.

According to an Economic Times report, the funding will be utilised to establish new state-of-the-art facilities in key cities, allowing the healthcare provider to reach more families with specialised medical care. An expert commented that this financial backing would enable Ankura Hospitals to scale up its operations, upgrade infrastructure and expand its network of hospitals.

Ankura Hospitals specialises in super-speciality tertiary and quaternary care services for women and children. The hospital chain currently operates 14 hospitals with over 1,500 beds across Telangana, Andhra Pradesh, Maharashtra and Odisha. It offers a comprehensive range of services, including normal deliveries, cesarean sections, fertility treatments, high-risk obstetrics and advanced gynaecological surgeries such as laparoscopic procedures.

Before this funding round, Ankura Hospitals had raised $17.8 million, the largest round being $8.31 million in July 2019 from private equity firm InvAscent.

With this latest investment, the hospital chain aims further to solidify its presence in India’s healthcare sector ensuring that high-quality medical services are more widely accessible to women and children across the country.

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk